Theralase Technologies Inc. (TLTFF) Q3 2024 Earnings Call Transcript
The most recent FDA approval belongs to BCG plus N-803, which has an initial complete response of 62%, falling to just 36% at 12 months. For technologies currently under clinical evaluation, slow-release gemcitabine, a chemotherapy drug, has an initial complete response of 76.7%, falling to 26% at 12 months.